Candesant Biomedical Receives FDA Clearance of Brella™¹, the First and Only 3-Minute SweatControl Patch™, to Significantly Reduce Primary Axillary Hyperhidrosis (Excessive Underarm Sweating)

/PRNewswire/ -- Candesant Biomedical ("Candesant"), a private medical device company focused on the development and commercialization of non-invasive...

Related Keywords

New Orleans ,Louisiana ,United States ,Canada ,American ,Americans ,Canadian ,Suzanne Haber ,Dee Anna Glaser ,Candesant Biomedical Inc ,Consumer Survey On Cosmetic Dermatologic Procedures ,International Hyperhidrosis Society ,Candesant Brella Early Experience Program ,A National ,Brella Early Experience Program ,Office Treatment ,Patch Technology ,Sweat Solutions ,Drug Administration ,Canadian Hyperhidrosis Advisory Committee ,American Society For Dermatologic Surgery ,American Academy Of Dermatology ,Significantly Improves Quality ,Including Reducing ,Negative Impact ,Daily Activities ,Single In Office ,Multicenter Pivotal ,Demonstrating Brella ,Treated Participants Maintained Sweat Reduction ,Three Months ,Candesant Biomedical ,Minute Sweatcontrol Patch ,Multichannel News Release ,Niquette Hunt ,Brella Sweatcontrol ,Brella Sweatcontrol Patch ,International Hyperhidrosis ,Brella Early Experience ,Excessive Sweating ,American Society ,Dermatologic Surgery ,Hyperhidrosis Disease Severity Scale ,American Academy ,Control Patch ,Trade Name ,Patient Experience With Hyperhidrosis ,National Survey ,Pilot Study ,Novel Device ,Subjects With Axillary ,Arch Dermatol Res ,Under Age ,Cosmetic Dermatologic ,Press Release ,Accessed Feb ,Excessive Axillary Sweating ,Primary Axillary ,Canadian Hyperhidrosis Advisory ,